Related Experiment Video
Updated: May 24, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
[Retrospective evaluation of pregabalin for cancer-related neuropathic pain]
1Department of Palliative Care, Saito Yukoukai Hospital, Ibaraki 567-0085.
Background:
Evidence to support the use of pregabalin in combination with opioid analgesics for the treatment of cancer-related neuropathic pain is limited.
Methods:
We carried out a retrospective investigation on patients hospitalized in our department with cancer-related neuropathic pain and under pregabalin treatment. Patients were divided into two groups: A group (= < 300 mg pregabalin daily) and B group (> 300 mg pregabalin daily). The two groups were compared in terms of a suite of factors (e. g., age starting and maimtenance dose of pregabaline, adverse effect).
Results:
Patient's age was significantly lower in the B group (> 300 mg pregabalin daily). Of the total number of patients involved in the study, 67% experienced mild and moderate somnolence.
Conclusions:
In this retrospective investigation, we conclude that the younger cancer patients may need lager doses of pregabalin to relieve cancer-related neuropathic pain. In addition, the mild and moderate somnolence occurs frequently when pregabalin is administered with opioid analgesics for the treatment of cancer-related neuropathic pain.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Analgesia and Pain Management
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists